The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Nurofen Rapid Relief Maximum Strength 400mg Liquid Capsules

Lexon Pharmaceuticals (Ireland) LimitedPPA23176/050/001

Main Information

Trade NameNurofen Rapid Relief Maximum Strength 400mg Liquid Capsules
Active SubstancesIbuprofen
Dosage FormCapsule, soft
Licence HolderLexon Pharmaceuticals (Ireland) Limited
Licence NumberPPA23176/050/001

Group Information

ATC CodeM01AE Propionic acid derivatives
M01AE01 ibuprofen


License statusAuthorised
Licence Issued11/11/2022
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of LicenceProduct is not subject to medical prescription, subject to the following conditions; Maximum Dose 400 mg Maximum Daily Dose 1200 mg Maximum Pack Size: 25 (400 mg)
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back